Nexalin Technology, Inc (NXL) Files IPO Registration Statement

Nexalin Technology, Inc (NASDAQ: NXL) has filed for a proposed IPO. The company currently anticipates pricing of $5-$7 per share.

The company describes itself as: "We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We have developed an easy-to-administer medical device — referred to as Generation 1 or Gen-1 – that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. This device emits our original waveform at 4 milliamps during treatment and is classified by the FDA as a Class II device."

Maxim Group LLC will serve as sole underwriter.

You May Also Be Interested In